Scleroderma News

DESTIN, Fla. — Challenging dermatologic conditions can take years to diagnose and almost as long to manage, according to a speaker at the Congress of Clinical Rheumatology East annual meeting.

In the final part of this series, Joseph Parambil, MD, walks us through the approach of managing pulmonary hypertension, reviews the pathophysiology and digs into the mechanisms and the differences in the medications.

Systemic sclerosis appears to have a “non-random” occurrence across the United States, with clusters of people diagnosed around environmentally contaminated Superfund sites, according to data published in Arthritis Care & Research.

Although chimeric antigen receptor T-cell therapy has raised hopes for long-term remission in autoimmune disease, it has several limitations that may be overcome instead through bispecific T-cell-engaging antibodies, according to a speaker.

The FDA has accepted an investigational new drug application for ALLO-329, an allogeneic chimeric antigen receptor T-cell therapy that may bypass lymphodepletion, paving the way for a phase 1 trial in lupus and other autoimmune diseases.

In this series, we dive into what rheumatologists should know about pulmonary hypertension, starting an interview with Joseph Parambil, MD, where we learn about the disease, when to suspect and how to work up!

Low doses of glucocorticoids added to immunosuppression yield no significant benefit for skin fibrosis in early diffuse cutaneous systemic sclerosis, according to data published in Arthritis Care & Research.

The odds of developing systemic lupus erythematosus or systemic sclerosis appear to significantly increase with the use of menopausal hormone therapy, according to data published in Rheumatology.

CMS has selected 15 new drugs for the next round of Medicare Part D price negotiations, according to a press release from HHS.